Since the gene set identified in tumors with an acquired resistance yields prognostic potential in both cohorts of patients with primary prostate cancer, these data indicate that the AR-driven processes that were identified in the samples with an acquired resistance may already be active in the primary tumor, driving prostate tumor progression and metastasis formation. This evidence concerns the gene AR and prostate carcinoma.